The Baxter/Claris Warning Letter: Out Of Spec, Out Of Mind
US FDA's inspection found a major problem in the operations of the facility that became Baxter’s when it acquired Claris: staff were blaming the laboratory for out-of-specification test results when they should have been fixing the manufacturing process. The result: a warning letter packed with assignments for the new owners.
You may also be interested in...
Agency’s revised OOS guidance clarifies positions on outlier test results, averaging of HPLC results and some finer points around OOS questions. These could marginally improve compliance but won’t impact industry with nearly the force of the original 2006 guidance or the 1993 court ruling that preceded it.
Data integrity failures are so yesterday. Now it’s all about poor investigations into out-of-specification results.
Apotex warning letter reflects FDA’s emphasis on company-wide quality systems and invalidated OOS results.